triumeq
viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - infecciones por vih - antivirales para uso sistémico - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.
dolutegravir comprimidos recubiertos 50 mg
siron pharma s.p.a. - dolutegravir - sin formulas
dolutegravir comprimidos recubiertos 50 mg
pharmaris chile s.p.a. - dolutegravir - sin formulas
dolutegravir/lamivudina/tenofovir disoproxil fumarato 50/300/300 comprimidos recubiertos
seven pharma chile s.p.a. - dolutegravir; lamivudina; tenofovir disoproxil fumarato - sin formulas
dolutegravir/lamivudina/tenofovir disoproxil fumarato 50/300/300 comprimidos recubiertos
siron pharma s.p.a. - dolutegravir sÓdico;lamivudina;tenofovir disoproxil fumarato - sin formulas
tivicay comprimidos dispersables 5 mg (dolutegravir)
glaxosmithkline chile farmacÉutica ltda. - dolutegravir - sin formulas
tivicay comprimidos recubiertos 10 mg (dolutegravir)
glaxosmithkline chile farmacÉutica ltda. - dolutegravir - sin formulas
tivicay comprimidos recubiertos 25 mg (dolutegravir)
glaxosmithkline chile farmacÉutica ltda. - dolutegravir - sin formulas
juluca
viiv healthcare b.v. - dolutegravir de sodio, rilpivirina hidrocloruro - infecciones por vih - antivirales para uso sistémico - juluca está indicado para el tratamiento del virus de inmunodeficiencia humana tipo 1 (vih-1) en adultos que son virológicamente-suprimida (arn del vih-1.
tivicay
viiv healthcare bv - dolutegravir - infecciones por vih - antivirales para uso sistémico - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.